Received Apr 16, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | U8510AA | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | UNK | 2164395 | — |
HCP called to report a TE for ROTATEQ and VAXELIS. Products were administered. No adverse effects reported, permission to contact is yes. No additional AE/No PQC.; No additional AE/No PQC.; This spontaneous report was received from other health professional (HCP) concerning a 7-month-old patient of unknown gender. The patient's pertinent medical history, past drug reactions or allergies, concurrent conditions and concomitant therapies were not provided. On an unknown date, the patient was vaccinated with Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ), (lot #2164395, expiration date: 22-Mar-2027) (vial 2, product quantity: 1); and with Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus (+)Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine Suspension for injection (VAXELIS) 0.5 ml, product quantity: 1 (Lot number U8510AA, expiration date 30-APR-2028). Both vaccines were administered as prophylaxis (route and anatomical location were not reported). On an unknown date, the HCP called to report a temperature excursion (TE) for Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus (+)Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine Suspension for injection (VAXELIS). Products were administered. No adverse effects reported.